首页|期刊导航|肿瘤学与转化医学(英文)|Immune checkpoint blockade in glioblastoma:overcoming barriers through mechanism-informed,biomarker-guided,and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials

Immune checkpoint blockade in glioblastoma:overcoming barriers through mechanism-informed,biomarker-guided,and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trialsOA

Immune checkpoint blockade in glioblastoma:overcoming barriers through mechanism-informed,biomarker-guided,and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials

Arpita Mukherjee

Shri Venkateshwara University,Gajraula,Uttar Prades,India

GlioblastomaImmune checkpoint inhibitorsTumor microenvironmentProgrammed death-1/programmed death-ligand 1Cytotoxic T-lymphocyte-associated antigen-4BiomarkersCombination therapyImmunotherapy resistance

GlioblastomaImmune checkpoint inhibitorsTumor microenvironmentProgrammed death-1/programmed death-ligand 1Cytotoxic T-lymphocyte-associated antigen-4BiomarkersCombination therapyImmunotherapy resistance

《肿瘤学与转化医学(英文)》 2026 (1)

15-37,23

10.1097/ot9.0000000000000120

评论